High-dose curcumin fails to produce lasting gut-microbiome changes in IBD patients

By Hugo Francisco de SouzaReviewed by Susha Cheriyedath, M.Sc.Mar 2 2026

Even at pharmacological doses that flood the colon but barely enter the bloodstream, curcumin’s effects on the gut microbiome proved temporary, highlighting the remarkable resilience of the human microbial ecosystem.

Study: Effect of curcumin on the gut microbiota of patients with ulcerative colitis, Crohn’s disease and healthy participants. Image Credit: Design_Cells / Shutterstock 

In a recent study published in the journal Scientific Reports, researchers investigated the impacts of curcumin on the human gut microbiota. The study specifically compared the effects of 6 g of curcumin consumed daily (“high dose”) in men (age = 18–65; n = 29) over 8 weeks.

Study analyses revealed that curcumin induced only temporary shifts in participants’ microbial composition. While the concentrations of beneficial bacteria like Faecalibacterium increased after four weeks, the microbiome surprisingly reverted to its baseline state by the end of the experiment (week eight), suggesting the gut ecosystem is highly resilient even against high-dose, sustained supplementation.

Background

Inflammatory Bowel Disease (IBD) is an umbrella term for a group of chronic diseases (primarily Crohn's disease [CD] and ulcerative colitis [UC]) characterized by prolonged inflammation of patients’ digestive tracts.

While the exact cause of these diseases is unknown, decades of research reveal a sharp decline in patients’ gut microbiota concentrations of beneficial bacteria involved in gut barrier maintenance (e.g., Clostridiales), suggesting that IBD’s mechanistic underpinnings are driven by a breakdown in the interactions between the immune system and the gut microbiota.

A staple of Indian traditional medicine for centuries, curcumin, the primary active ingredient of the turmeric root with established anti-inflammatory properties, is increasingly being investigated as a safe and natural intervention against IBD.

Unfortunately, these studies have found that curcumin has extremely poor bioavailability: when turmeric is consumed, it is rapidly metabolized and poorly absorbed, resulting in only a small fraction of the active curcumin reaching the bloodstream.

Researchers have consequently proposed an alternative hypothesis: if curcumin is localized in the gut, could it serve as a substrate for the growth of beneficial bacteria that restore the gut barrier and reverse IBD? Previous research has yielded inconclusive findings, a demerit attributed to their use of curcumin in combination with other medications or supplements.

About the study

The present study aims to address this knowledge gap and inform future IBD interventions by investigating the isolated effects of curcumin on the microbiome in a controlled, high-dose setting.

The study leveraged an open-label, single-arm study involving 29 male participants (ages 18 to 65). The participants' cohort notably comprised 10 patients with UC, 10 with CD (both groups in remission), and 9 healthy volunteers.

The experimental intervention involved participants consuming 3 g of curcumin twice daily (a total of 6 g per day) for 8 weeks. This represents a substantially higher (yet safe) curcumin dosage than that obtained from regular dietary intake or recommended supplementation.

The study collected participants’ blood, urine, and stool samples at three key time points: baseline (week 0), week 4, and week 8. Sample analyses were primarily carried out via 16S rRNA amplicon sequencing to characterize and quantify participants’ gut bacteria composition, thereby allowing the study to track temporal changes in the microbiome.

The study further leveraged high-throughput liquid chromatography-mass spectrometry (HPLC-MS/MS) to measure exactly how much curcumin ended up in the participants' blood versus their excretory waste.

Study findings

HPLC-MS/MS analyses supported previous reports of curcumin's poor bioavailability, revealing that while active (unconjugated) curcumin levels in the blood were near or below quantification limits, fecal concentrations were approximately 6,000 times higher than what was observed in participants’ plasma samples. This notably confirmed the hypothesis that gut bacteria are exposed to high concentrations of unabsorbed curcumin.

However, despite this sustained exposure to significantly higher-than-baseline curcumin concentrations, 16S rRNA amplicon analyses revealed that the gut microbiome demonstrated remarkable resilience to compositional variation.

Specifically, analyses of participants' gut microbiome alpha-diversity (a measure of observed amplicon sequence variants (ASVs), a proxy for richness) revealed no change in the overall richness of detected taxa over the 8-week study.

While participants’ beta-diversity (a measure of species composition) demonstrated a statistically significant shift in microbial community structure at week 4 (R2 = 0.0076, p = 0.0001), establishing an initial bacterial response to the intervention, beta-diversity returned to baseline by week 8 (p = 0.057). Importantly, the intervention explained only a very small proportion of overall microbial variance (approximately 0.76%), underscoring the modest effect size of the observed shift.

Analyses of specific bacterial populations revealed that some beneficial bacteria, particularly Roseburia faecis and Faecalibacterium, increased in their relative abundance by week 4. These species have previously been associated with the production of butyrate, a compound that supports gut barrier integrity. Unfortunately, as with the broader diversity metrics, these specific populations also drifted back to baseline levels by the end of the study. The authors further noted considerable interindividual variability in microbiome composition and response magnitude across participants, which likely contributed to the transient and modest nature of the overall findings.

Encouragingly, curcumin was generally well tolerated, and participants reported no sustained increases in their disease activity scores (HBI and SSCAI). One participant withdrew after week 4 due to shingles requiring medical treatment; a direct causal relationship to curcumin could not be established.

Conclusions

The present study highlights that while curcumin is safe and achieves high local concentrations in the colon, it does not drive sustained restructuring of the gut microbiota in IBD patients in remission or healthy individuals.

It further reveals the resilience of the human microbiome to curcumin-induced compositional change, underscoring that this bioactive alone is unlikely to induce durable microbiome restructuring in this small, exploratory cohort, which was not powered to detect clinical efficacy outcomes, and that its capacity to reverse IBD-associated dysbiosis remains uncertain.